Clinical trial
A Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment Alone for Adjuvant Therapy in Patients With High-risk Factor Squamous Cell Carcinoma of the Head and Neck After Surgery.
NCT06772428 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment Alone for Adjuvant Therapy in Patients With High-risk Factor Squamous Cell Carcinoma of the Head and Neck After Surgery.
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- January 1, 2025
- Completion date
- December 31, 2027
- Enrollment
- 96 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck squamous cell carcinoma; underwent surgery within 6 weeks and postoperative assessment indicated high-risk factors